Effect of Tofogliflozin on Cardiac Function: Potential Link Between Ketone Bodies and the Heart

Eiji Kutoh


This report describes the effect of tofogliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), on cardiac function and its related parameters including ketone bodies (acetoacetate and beta-hydroxybutyrate). One case received and two cases discontinued tofogliflozin. Changes of cardiometabolic parameters were compared at 3 months. A 65-year-old patient with decreased heart function received tofogliflozin 20 mg/day. Left ventricular ejection fraction (EF), functional shortening (%FS), or acetoacetate/beta-hydroxybutyrate levels were increased. A 68-year-old patient with normal heart function discontinued tofogliflozin 20 mg/day. EF, %FS or acetoacetate/beta-hydroxybutyrate levels were decreased. A 60-year-old patient with slightly decreased heart function discontinued tofogliflozin. No changes of EF, %FS, or acetoacetate/beta-hydroxybutyrate levels were noted. Taken together, these results suggest that ketone bodies and the heart function appear to be related (concomitant changes by tofogliflozin) and that tofogliflozin might have effects on cardiac function through modulating ketone bodies.

J Endocrinol Metab. 2017;7(3):94-97
doi: https://doi.org/10.14740/jem396e


Tofogliflozin; SGLT2i; Cardiac function; Ketone bodies; Heart

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.